Drug intelligence / Profile preview

AMT-116

Development stage: Phase 3
Lead developer: Multitude Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AMT-116 is a first-in-class antibody-drug conjugate (ADC) developed by Multitude Therapeutics Inc. It comprises a humanized anti-CD44v9 IgG1 antibody conjugated to KL610023, a novel belotecan-derived topoisomerase I inhibitor, via a cleavable hydrolysable linker. The drug targets CD44v9, which is highly expressed in various solid tumors, and delivers the topoisomerase I inhibitor payload to exert its antitumor activity. It is currently being evaluated in Phase 1/2 clinical trials for advanced solid tumors.

Targets

CD44v9 (CD44 variant 9)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on AMT-116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMT-116.

Explore the full profile